Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CLL-1 antigen-armed antibody
- Development stage
- Preclinical
- Lead developer
- Universitat Heidelberg
- Modality
- Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
The anti-CLL-1 antigen-armed antibody (AgAb) is an experimental immunotherapy designed for the treatment of acute myeloid leukemia (AML). This novel therapeutic modality consists of a monoclonal antibody targeting the C-type lectin-like molecule-1 (CLL-1/CLEC12A), which is highly expressed on AML blasts and leukemic stem cells, fused to immunodominant epitopes from the Epstein-Barr virus (EBV). Upon binding to CLL-1, the AgAb undergoes receptor-mediated endocytosis, delivering the viral epitopes to the endosomal compartments of the leukemia cells. These epitopes are then processed and presented on the cell surface via MHC class II molecules. This mechanism redirects the patient's pre-existing, endogenous memory EBV-specific CD4+ cytotoxic T cells to recognize and lyse the AML cells. By harnessing potent anti-viral immunity, this approach aims to overcome the typically low immunogenicity of malignant myeloid cells.
- Other names
- CLL-1 AgAbCLL1 AgAbCLL 1 AgAbanti-CLEC12A antigen-armed antibodyanti-CLEC-12A antigen-armed antibodyanti-CLEC 12A antigen-armed antibodyCLL-1 antigen-armed antibodyCLL1 antigen-armed antibodyCLL 1 antigen-armed antibody
02
Targets
CLEC12A
Beyond the preview
Go deeper on anti-CLL-1 antigen-armed antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CLL-1 antigen-armed antibody.